Find the latest episode of "The Uncertain Hour" here. Listen
A prescription bottle label for Pfizer's Lipitor Tim Boyle, Getty Images

Pfizer fizzles

Stacey Vanek Smith Dec 4, 2006
A prescription bottle label for Pfizer's Lipitor Tim Boyle, Getty Images

TEXT OF STORY

BOB MOON: So what do you do when Plan B fails? That’s what investors seem to be asking the world’s biggest drugmaker, Pfizer, this morning. An advanced cholesterol drug that was supposed to take the place of its top-selling brand Lipitor has suddenly gone from the company’s best hope, to hopeless, and shares of Pfizer are fizzling this morning. Marketplace’s Stacey Vanek-Smith reports.


STACEY VANEK-SMITH: Pfizer was hoping lightening would strike twice in the same spot.

Its cholesterol-lowering Lipitor is the best-selling drug in the world. It brings in more than $10 billion a year, but Lipitor’s patent will expire in a few years, and Pfizer is scrambling to find a replacement.

The new drug was meant to treat heart disease by raising good cholesterol.

Mark Ravera is principal analyst at Strategic Pharma consulting group. He says losing this drug is a huge blow.

MARK RAVERA: It really would have been potentially a very, very big drug. This is going to be a difficult one to replace for them, because of the time it takes to develop a new drug, bring something new and also of blockbuster potential through the pipeline.

Without a strong follow-up to the hugely successful Lipitor, Pfizer may have to rely on cost-cutting and corporate buyouts to keep its edge in the ultra-competitive pharma industry.

In New York, I’m Stacey Vanek-Smith for Marketplace.

Marketplace is on a mission.

We believe Main Street matters as much as Wall Street, economic news is made relevant and real through human stories, and a touch of humor helps enliven topics you might typically find…well, dull.

Through the signature style that only Marketplace can deliver, we’re on a mission to raise the economic intelligence of the country—but we don’t do it alone. We count on listeners and readers like you to keep this public service free and accessible to all. Will you become a partner in our mission today?

Your donation is critical to the future of public service journalism. Support our work today – for as little as $5 – and help us keep making people smarter.